原发性中枢神经系统淋巴瘤:全身CT与FDG PET/CT用于初始全身影像检查的诊断率
回顾性纳入304例经立体定向脑活检确诊的原发性中枢神经系统淋巴瘤患者,评估初始全身增强胸腹盆CT和/或全身FDG PET/CT的诊断率。初始分期诊断率为2%(6/304),假阳性13例(4%);复发时诊断率为1.5%(1/68),假阳性4/68(6%);2009年前后诊断率无差异(P=0.82)。
要点
- 疑似原发性中枢神经系统淋巴瘤初始分期全身影像诊断率仅2%(6/304),假阳性率4%(13/304)。
- 复发时全身影像诊断率1.5%(1/68),假阳性率6%(4/68)。
- 2009年前后诊断率无差异(P=0.82),提示技术变化未影响诊断率。
核心结论
- 增强胸腹盆CT和/或全身FDG PET/CT用于疑似原发性中枢神经系统淋巴瘤初始分期及复发评估的诊断率均低。
研究设计与样本
- 回顾性研究,纳入1998年1月至2018年10月单中心三级医院连续成人(年龄>18岁)304例,均经立体定向脑活检确诊新发原发性中枢神经系统淋巴瘤,治疗前接受增强胸腹盆CT和/或全身FDG PET/CT检查。
诊断标准与关键数值
- 初始分期全身影像诊断率2%(6/304,95%CI:0.7%,4.3%),假阳性13/304(4%,95%CI:2.3%,7.2%)。
- 复发时全身影像诊断率1.5%(1/68,95%CI:0.0%,7.9%),假阳性4/68(6%,95%CI:1.6%,14.4%)。
- 2009年前与2009年及以后诊断率无差异(P=0.82)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Updated guidelines for suspected primary central nervous system lymphoma (PCNSL) are lacking. Purpose To investigate the diagnostic yield of initial systemic imaging in patients suspected of having PCNSL by using contrast material-enhanced chest and abdominopelvic CT and/or whole-body fluorine 18 fluorodeoxyglucose (FDG) PET/CT. Materials and Methods This retrospective study included 304 patients examined at a single tertiary hospital between January 1998 and October 2018. Consecutive adults (age >18 years) who were confirmed to have newly diagnosed PCNSL on the basis of findings at stereotactic brain biopsy were recruited. All patients were examined with contrast-enhanced chest and abdominopelvic CT and/or whole-body FDG PET/CT before initiation of PCNSL treatment. The diagnostic yield of CT and PET/CT was determined before therapy and at the time of recurrence in the brain. A χ2 test was performed to compare the diagnostic yield according to study date in order to assess for possible changes in technology during the study period. Results A total of 304 patients (180 men with a mean age [±standard deviation] of 58 years ± 13 and 124 women with a mean age of 59 years ± 13) were included. The diagnostic yield of CT and PET/CT for initial staging was 2% (six of 304 patients; 95% confidence interval [CI]: 0.7%, 4.3%), and these tests yielded false-positive findings in 13 of the 304 patients (4%; 95% CI: 2.3%, 7.2%). Diagnostic yield did not differ between patients evaluated before 2009 and those evaluated in 2009 and later (P = .82). The diagnostic yield of systemic imaging at recurrence was 1.5% (one of 68 patients; 95% CI: 0.0%, 7.9%), and these tests yielded false-positive findings in four of those 68 patients (6%; 95% CI: 1.6%, 14.4%). Conclusion Contrast-enhanced chest and abdominopelvic CT and/or whole-body fluorine 18 fluorodeoxyglucose PET/CT for initial staging, as well as for recurrence of suspected primary central nervous system lymphoma, had a low diagnostic yield. © RSNA, 2019 See also the editorial by Jara in this issue.
引用
- Suh CH, Kim HS, Park JE, et al. Primary Central Nervous System Lymphoma: Diagnostic Yield of Whole-Body CT and FDG PET/CT for Initial Systemic Imaging. Radiology. 2019. PMID: 31237497. doi:10.1148/radiol.2019190133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。